Los Angeles Capital Management LLC Grows Stock Holdings in LifeMD, Inc. (NASDAQ:LFMD)

Los Angeles Capital Management LLC increased its holdings in shares of LifeMD, Inc. (NASDAQ:LFMD) by 852.6% in the 3rd quarter, HoldingsChannel reports. The firm owned 121,585 shares of the company’s stock after acquiring an additional 108,822 shares during the quarter. Los Angeles Capital Management LLC’s holdings in LifeMD were worth $637,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in LFMD. Quest Partners LLC purchased a new position in shares of LifeMD during the 2nd quarter valued at about $31,000. nVerses Capital LLC purchased a new position in LifeMD during the third quarter valued at approximately $46,000. CWM LLC acquired a new position in LifeMD in the third quarter valued at approximately $59,000. SG Americas Securities LLC purchased a new stake in LifeMD in the 3rd quarter worth approximately $70,000. Finally, EntryPoint Capital LLC acquired a new stake in shares of LifeMD during the 1st quarter worth approximately $89,000. 35.52% of the stock is currently owned by institutional investors and hedge funds.

LifeMD Stock Down 8.1 %

Shares of NASDAQ LFMD opened at $5.49 on Friday. LifeMD, Inc. has a 52-week low of $3.99 and a 52-week high of $12.88. The company has a quick ratio of 0.78, a current ratio of 0.83 and a debt-to-equity ratio of 10.83. The company’s 50-day simple moving average is $4.99 and its 200-day simple moving average is $6.38. The firm has a market cap of $237.57 million, a price-to-earnings ratio of -8.57 and a beta of 1.23.

Wall Street Analysts Forecast Growth

LFMD has been the topic of a number of recent analyst reports. HC Wainwright reissued a “buy” rating and set a $12.00 price target on shares of LifeMD in a report on Monday, November 11th. B. Riley began coverage on shares of LifeMD in a research note on Friday, August 23rd. They set a “buy” rating and a $11.00 target price on the stock. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $15.00 price target on shares of LifeMD in a research note on Friday, September 20th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $12.00.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.